Neon Therapeutics (NASDAQ:NTGN) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
This is a summary of current recommendations and price targets for Neon Therapeutics and Champions Oncology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Neon Therapeutics and Champions Oncology’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neon Therapeutics||N/A||N/A||-$47.53 million||N/A||N/A|
|Champions Oncology||$20.24 million||5.41||-$1.47 million||($0.14)||-68.07|
Champions Oncology has higher revenue and earnings than Neon Therapeutics.
This table compares Neon Therapeutics and Champions Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
71.1% of Neon Therapeutics shares are held by institutional investors. Comparatively, 50.0% of Champions Oncology shares are held by institutional investors. 44.3% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Champions Oncology beats Neon Therapeutics on 6 of the 8 factors compared between the two stocks.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Neon Therapeutics, Inc. has a clinical trial collaboration with Natera, Inc. to assess the treatment response to personal cancer vaccine. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Champions Oncology Company Profile
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.